Sadeghi N, Khalife S, Mascarella MA, et al. - Among 54 patients with HPV-positive oropharynx cancer (OPC), researchers evaluated the ability of tumor volume reduction on imaging to anticipate pathological response to neoadjuvant chemotherapy. The sample consisted of patients with HPV-positive OPC registered in a clinical trial of neoadjuvant chemotherapy followed by surgery. Study participants had three cycles of induction chemotherapy (cisplatin/docetaxel); prechemotherapy and postchemotherapy imaging have been obtained. According to this prospective observational study, the complete pathologic response (pCR) rate at primary and nodal sites were 72% and 57%, respectively. Data reported that tumor volume reduction of ≥ 90% following induction chemotherapy anticipated pCR of the primary tumor. Neoadjuvant chemotherapy accompanied by definitive transoral surgery is a new paradigm worth investigating further, and MRI is a reliable modality for assessing preoperative response.